{
    "clinical_study": {
        "@rank": "18132", 
        "arm_group": [
            {
                "arm_group_label": "Beijing region", 
                "description": "include six hospitals"
            }, 
            {
                "arm_group_label": "Guangdong Province", 
                "description": "include 3 hospitals"
            }, 
            {
                "arm_group_label": "Jiangsu province", 
                "description": "include 3 hospitals"
            }, 
            {
                "arm_group_label": "Hebei province", 
                "description": "include 6 hospitals"
            }, 
            {
                "arm_group_label": "Hubei Province", 
                "description": "include 7 hospitals"
            }, 
            {
                "arm_group_label": "Shanxi province", 
                "description": "include 3 hospitals"
            }, 
            {
                "arm_group_label": "Jiangxi province", 
                "description": "include 3 hospitals"
            }, 
            {
                "arm_group_label": "Jilin province", 
                "description": "include 6 hospitals"
            }, 
            {
                "arm_group_label": "Sichuan province", 
                "description": "include 3 hospitals"
            }, 
            {
                "arm_group_label": "Shaanxi province", 
                "description": "include 3 hospitals"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators aimed to examine the psychotropic prescription pattern in China."
        }, 
        "brief_title": "The Third Survey of Prescription Pattern of Psychotropic Drugs in China", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Prescription", 
        "condition_browse": {
            "mesh_term": [
                "Bipolar Disorder", 
                "Schizophrenia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria: aged 18-65, inpatient or  outpatient, Patient must be willing and able\n        to give written informed consent,the patient suffers from schizophrenia or depression or\n        bipolar disorder -\n\n        Exclusion Criteria:aged<18or aged>65\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "schizophrenia, depression and bipolar disorder patients"
            }
        }, 
        "enrollment": {
            "#text": "7000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01668810", 
            "org_study_id": "RISSCH4255"
        }, 
        "intervention_browse": {
            "mesh_term": "Psychotropic Drugs"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "prescription", 
            "schizophrenia", 
            "depression", 
            "bipolar disorder"
        ], 
        "lastchanged_date": "August 17, 2012", 
        "location": {
            "contact": {
                "email": "si.tian-mei@163.com", 
                "last_name": "Tianmei Si, PhD.", 
                "phone": "8610-82801960"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100191"
                }, 
                "name": "Institute of mental health, Peking University"
            }, 
            "investigator": {
                "last_name": "Tianmei Si, PhD.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "10", 
        "official_title": "The Third Survey on China Psychotropic Prescription for Schizophrenia, Depression and Bipolar Disorder", 
        "overall_contact": {
            "email": "suyunai@gmail.com", 
            "last_name": "Yun-Ai Su, Phd.", 
            "phone": "8610-82801960"
        }, 
        "overall_official": {
            "affiliation": "Peking University", 
            "last_name": "Xin Yu, MD.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Anticipated"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01668810"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking University", 
            "investigator_full_name": "Si Tianmei", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Peking University", 
        "sponsors": {
            "collaborator": {
                "agency": "Xian-Janssen Pharmaceutical Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Peking University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Observational Model: Ecologic or Community, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "July 2012"
    }
}